2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3532 Spatial transcriptomics uncovers distinct microenvironmental programs driving response to brentuximab vedotin and pembrolizumab in R/R CTCL

Arjun Ravishankar, MBBS, Archibald Enninful, PhD2, Martin Matthews3, Jennifer VanOudenhove, PhD4, Stephanie Halene, MD5, Michael Girardi, MD, FAAD6, Francine Foss, MD7, David C Fisher, MD8, Rong Fan9, Tarsheen Sethi, MD10, Mina L Xu, MD11
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale University, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Yale School of Medicine, New Haven, Connecticut, United States
5 Yale School of Medicine, New Haven, Connecticut, United States
6 Yale School of Medicine, New Haven, Connecticut, United States
7 Yale School of Medicine, New Haven, Connecticut, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Yale University, New Haven, Connecticut, United States
10 Yale School of Medicine, New Haven, Connecticut, United States
11 Yale School of Medicine, New Haven, Connecticut, United States

Introduction

Relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) remains incurable, as available agents produce low response rates and rarely achieve durable remissions. Brentuximab vedotin (BV), a CD30 directed antibody-drug conjugate, induces immunogenic cell death and shows preclinical evidence of synergy with immune checkpoint inhibitors (ICI). An ongoing multicenter Phase 2 trial of BV combined with pembrolizumab (BV/Pembro) in R/R CD30+ CTCL (NCT05313243) has surpassed its prespecified futility threshold.

Single-cell RNA and TCR sequencing in aggressive CTCL demonstrates enrichment of immunosuppressive macrophages and dysfunctional T cells. Emerging spatial atlases indicate that malignant T cells actively organize protective immunosuppressive niches, however, the evolution of these spatial neighborhoods with treatment remains undefined. We hypothesized that patients who respond to BV/Pembro exhibit distinct tumor-microenvironment (TME) interactions and applied paired spatial transcriptomics and spatial proteomics to investigate underlying mechanisms.

Methods

Skin biopsies were collected from patients enrolled on the BV/Pembro trial at baseline and after 3 cycles of treatment, and clinical responders and non-responders were identified as specified by the trial protocol. Non-clinical trial biopsies for controls were obtained from the archive at Yale Department of Pathology.

We generated spatial transcriptomics data using 10X Xenium 5000-gene panel from 43 skin biopsies: 6 normal controls, 16 non-trial R/R CTCL, and 21 trial biopsies with R/R CTCL (12 pre-treatment biopsies from 9 patients, 9 post-cycle 3 biopsies from 8 patients, with 6 patients having matched samples). Data was analyzed in R using Seurat. Following hierarchical sub-clustering into epithelial, stromal, and immune compartments, cell types were annotated via upregulated marker genes. Compositional shifts were assessed via Kruskal-Wallis tests (Benjamini-Hochberg correction), and transcriptional reprogramming was evaluated using DESeq2 and GSEA (MSigDB Hallmark).

Multiplex immunofluorescence on these same TMAs are ongoing and will provide more definitive spatial confirmation of functional cellular states, surface receptor expression, and active therapeutic targets within the CTCL microenvironment.

Results

Analyzing >600,000 cells from 43 biopsies, R/R CTCL exhibited significantly enriched CXCL13+ malignant T-cells, activated keratinocytes, and IFN-activated M1-macrophages compared to normal skin. Differential gene expression and gene set enrichment analysis (GSEA) revealed TME-wide reprogramming with pan-compartment upregulation of interferon, JAK/STAT3, and PI3K/AKT/mTOR signaling. Immune compartments showed marked enrichment for proliferative/metabolic pathways (E2F, MYC, mTORC1, OXPHOS), while epithelium upregulated TNFα/NF-κB and P53 pathways.

Following treatment with BV/Pembro, responders demonstrated TME normalization with downregulation of pre-treatment inflammatory/pro-tumorigenic programs (TNFα/NF-κB, JAK/STAT3, EMT, angiogenesis) alongside decreased malignant T-cells and cancer associated fibroblasts (CAFs), and increased Pi16+ fibroblasts and plasma cells. Non-responders failed to resolve these inflammatory/pro-tumorigenic programs, retaining immune proliferation, active epithelial cell cycling, and stromal interferon signaling.

Notably, pre-treatment profiles predicted treatment outcomes. Responders exhibited a proliferative epithelium with upregulation of E2F, G2M, and MYC pathways, and immune-permissive stroma primed for immunogenic cell death. Conversely, non-responders harbored a pre-existing, treatment-resistant desmoplastic TME defined by chronic inflammation, immune exclusion, and pan-compartment interferon, hypoxia, and NF-κB signaling.

Conclusions

Our analysis demonstrates that successful BV/Pembro treatment normalizes a highly inflamed, pro-tumorigenic microenvironment in R/R CTCL. Crucially, distinct pre-treatment spatial architectures predict a clinical response, with responders exhibiting an immune-permissive stroma while non-responders remain restricted by a desmoplastic, immune-excluded niche. Ongoing neighborhood analyses aim to translate transcriptomic signatures into clinically actionable predictive biomarkers. Furthermore, planned multiplex immunofluorescence will orthogonally validate targets at the protein level to definitively guide future patient stratification and advance drug discovery efforts.

Arjun Ravishankar, MBBS: No relevant conflicts of interest to declare.